AstraZeneca blood clot worries complicate bid to vaccinate the world

Reviews by UK and EU regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on

Growing worries that AstraZeneca Plc’s Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.
 

Reviews by UK and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.

Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still